Cargando…
A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma
Bronchial asthma is recognized as a highly prevalent health problem in the developed and developing world with significant social and economic consequences. Increased asthma severity is not only associated with enhanced recurrent hospitalization and mortality but also with higher social costs. The p...
Autores principales: | D’Amato, Gennaro, Salzillo, Antonello, Piccolo, Amedeo, D’Amato, Maria, Liccardi, Gennaro |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374942/ https://www.ncbi.nlm.nih.gov/pubmed/18472983 |
Ejemplares similares
-
Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review
por: D’Amato, Gennaro, et al.
Publicado: (2014) -
Omalizumab and IgE in the Control of Severe Allergic Asthma
por: Gon, Yasuhiro, et al.
Publicado: (2022) -
Omalizumab in the management of patients with allergic (IgE-mediated) asthma
por: Sandström, Thomas
Publicado: (2009) -
Inhibition of IgE and IgE/anti-IgE mediated responses in mast cells by Omalizumab
por: Kulka, M, et al.
Publicado: (2010) -
Oxytocin: an unexpected risk for cardiologic and broncho-obstructive effects, and allergic reactions in susceptible delivering women
por: Liccardi, Gennaro, et al.
Publicado: (2013)